製品番号: HY-100354

Copy Link Print Information

C16-Ceramide

(別名: C16セラミド)

7 Cited Publications

カスタマーレビュー

Based on 7 publication(s) in Google Scholar

C16-Ceramide (d18:1/16:0) is a natural small molecule activating p53 through the direct and selective binding.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.92%
CAS 番号: 24696-26-2
分子式: C₃₄H₆₇NO₃
分子量:537.90

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

C16-Ceramide (d18:1/16:0) 構造式

CAS 番号: 24696-26-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

C16-Ceramide (d18:1/16:0) is a natural small molecule activating p53 through the direct and selective binding^[1].

IC₅₀ & Target

p53^[1], Apoptosis^[2]

Endogenous Metabolite アイソフォーム固有の製品をすべて表示 :

体外実験

C16-Ceramide (d18:1/16:0) interacts with p53 within its core domain. p53 forms complex with natural C16-Ceramide (d18:1/16:0) in the cell^[1].
C16-Ceramide (d18:1/16:0) (2.5-50 μM; 0-48 h) strongly decreased HCT116 cell viability in a time- and concentration-dependent manner^[2].
C16-Ceramide (d18:1/16:0) (12 μM; 48 h) induces apoptosis through Btf (Bcl-2-associated transcription factor) in HCT116 cells^[2].
C16-Ceramide (d18:1/16:0) (12 μM; 0-6 h) and Btf expression up-regulate p53 and BAX expression. C16-Ceramide (d18:1/16:0) down-regulates Mdm2 expression via Btf^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

HCT116 cells
Concentration:

2.5, 5, 10, 12, 20, 50 µM
Incubation Time:

0-48 h
Result:

Strongly decreased cell viability in a time- and concentration-dependent manner.

Western Blot Analysis^[2]

Cell Line:

HCT116 cells
Concentration:

12 μM
Incubation Time:

1, 3 and 6 h
Result:

Increased PARP cleavage, decreased pro-caspase 3. Decreased the levels of stratifin and stathmin, increased the expression of prohibitin and Btf. RNAi-mediated Btf depletion also partially inhibited BAX expression after the treatment. Significantly decreased luciferase activity and Mdm2 protein expression levels.

化学情報

CAS 番号 24696-26-2
性状 Solid
分子量 537.90
分子式 C₃₄H₆₇NO₃
Color White to off-white
SMILES

CCCCCCCCCCCCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O
別名

C16セラミド
Structure Classification
- Alkaloids
- Other Alkaloids
Initial Source
- Endogenous metabolite
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (7)

All Cell Proliferation/Viability AssayRT-PCRWB

Sort by:

Journal Impact Factor

ACS Nano

Cell-Free Osteoarthritis Treatment with Sustained-Release of Chondrocyte-Targeting Exosomes from Umbilical Cord-Derived Mesenchymal Stem Cells to Rejuvenate Aging Chondrocytes. [Abstract]

2023 Jul 25;17(14):13358-13376. PMID: 37439514

C16-Ceramide (d18:1/16:0) purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Jul 25;17(14):13358-13376. [Abstract]

C16-Ceramide (5 μM/10 μM). Cell viability assessed by live (green)/dead (red) staining.
Cancer Lett

AKT1/FOXP3 axis-mediated expression of CerS6 promotes p53 mutant pancreatic tumorigenesis. [Abstract]

2021 Dec 1:522:105-118. PMID: 34343636

C16-Ceramide (d18:1/16:0) purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2021 Dec 1:522:105-118. [Abstract]

Cell proliferation experiments were conducted in PANC-1 shNT, shCerS6+EV, shCerS6+rWT, and shCerS6+rR131A cell lines with or without different doses of C16-ceramide, and in CFPAC-1 EV, WT, or R131A cell lines with or without different doses of cell-permeable C16-ceramide (PC16: 0.5 μM/12.5 μM).
Lipids Health Dis

High-fat stimulation induces atrial structural remodeling via the TPM1/P53/SHISA5 Axis. [Abstract]

2025 Apr 12;24(1):138. PMID: 40221727

C16-Ceramide (d18:1/16:0) purchased from MedChemExpress. Usage Cited in: Lipids Health Dis. 2025 Apr 12;24(1):138. [Abstract]

Western blot analysis of the expression of P53, SHISA5, type I collagen, MMP2, p-IRE1α, GRP78, p-JNK, P62 and LC3-II proteins in HCF cells after activation of P53 by C16-ceramide (10 µM, 24 h).
Drug Des Devel Ther

Exploratory Study on the Role of Emodin in Alleviating MPTP-Induced Neurotoxicity: A Focus on p53-Ferroptosis Signaling. [Abstract]

2025 Dec 1:19:10645-10660. PMID: 41356603

C16-Ceramide (d18:1/16:0) purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2025 Dec 1:19:10645-10660. [Abstract]

The relative mRNA levels of TFRC and ACSL4 in SH-SY5Y cells treated with C16-Ceramide (50 μM).

C16-Ceramide (d18:1/16:0) purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2025 Dec 1:19:10645-10660. [Abstract]

Western blot analysis of C16-Ceramide (50 μM) confirmed that activation of p53 weakened the inhibitory effect of EMD on ferroptosis.
SSRN

2025 Nov 8.
SSRN

2025 Aug 6.
SSRN

2025 Jan 8.

溶剤 & 溶解度

体外:

DMF : 20 mg/mL (37.18 mM; ultrasonic and warming and heat to 60°C)

Ethanol : 10 mg/mL (18.59 mM; ultrasonic and warming and heat to 60°C)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8591 mL

9.2954 mL

18.5908 mL

5 mM

0.3718 mL

1.8591 mL

3.7182 mL

10 mM

0.1859 mL

0.9295 mL

1.8591 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2 mg/mL (3.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% HPMC/1% Tween-80 in Saline water

Solubility: 4.95 mg/mL (9.20 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 15% Solutol HS 15 10% Cremophor EL 35% PEG400 40% Water

Solubility: 5 mg/mL (9.30 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (269 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Fekry B, et al. C16-ceramide is a natural regulatory ligand of p53 in cellular stress response. Nat Commun. 2018 Oct 8;9(1):4149. [Content Brief]

[2]. Rénert AF, et al. The proapoptotic C16-ceramide-dependent pathway requires the death-promoting factor Btf in colon adenocarcinoma cells. J Proteome Res. 2009 Oct;8(10):4810-22. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMF	1 mM	1.8591 mL	9.2954 mL	18.5908 mL	46.4770 mL
	5 mM	0.3718 mL	1.8591 mL	3.7182 mL	9.2954 mL
	10 mM	0.1859 mL	0.9295 mL	1.8591 mL	4.6477 mL
	15 mM	0.1239 mL	0.6197 mL	1.2394 mL	3.0985 mL
DMF	20 mM	0.0930 mL	0.4648 mL	0.9295 mL	2.3239 mL
	25 mM	0.0744 mL	0.3718 mL	0.7436 mL	1.8591 mL
	30 mM	0.0620 mL	0.3098 mL	0.6197 mL	1.5492 mL

Keywords

C16-Ceramide (d18:1/16:0)

7 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

C16-Ceramide

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Lipid Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Glutamine Metabolism Compound Library

Alkaloids Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Human Metabolite Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 C16-Ceramide (d18:1/16:0)

Endogenous Metabolite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (7)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

C16-Ceramide (d18:1/16:0) 関連分類

HY-100354 関連分類